Clinical Trials Logo

Clinical Trial Summary

This study will compare how well EXC 001 works versus placebo in reducing the appearance of scars in subjects undergoing elective abdominoplasty. The study will also evaluate the safety of EXC 001 in healthy adult subjects.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01038297
Study type Interventional
Source Pfizer
Contact
Status Completed
Phase Phase 2
Start date December 1, 2009
Completion date July 7, 2010

See also
  Status Clinical Trial Phase
Completed NCT00892723 - A Study to Evaluate the Safety and Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloid Scars Phase 2
Active, not recruiting NCT06312527 - Mepiform in Simultaneous Bilateral TKA N/A
Completed NCT00825916 - A Study to Evaluate the Safety and Efficacy of AZX100 Drug Product Following Excision of Keloid Scars Phase 2
Completed NCT01640912 - Evaluation of the Safety, Pharmacokinetics, and Preliminary Effect on Scar Formation by RXI-109 Phase 1
Completed NCT04707131 - A Study of Single Ascending Dose of LEM-S401 in Healthy Participants Phase 1
Recruiting NCT04722705 - Combined Intense Pulsed Light (IPL) With Fractional Erbium:YAG Laser Ablation in Scar Prevention N/A
Terminated NCT01826942 - Scar Prevention Using Fractional Carbon Dioxide Laser Treatment N/A
Completed NCT00811577 - A Phase 2a Study to Evaluate the Safety and Efficacy of AZX100 in Trocar Sites of Arthroscopic Shoulder Surgery Patients Phase 2
Completed NCT01037985 - Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty Phase 2
Completed NCT01037413 - Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery Phase 2
Completed NCT01780077 - Evaluation of Safety, PK, and Preliminary Effects on Scar Formation of Multiple Intradermal Administrations of RXI-109 Phase 1